The vaccine components of the PBS Vax™ platform have been advanced through Phase 1 safety and immunogenicity testing. Data confirm the Profectus PBS Vax™ system is enhancing immune responses in new ways:
- VesiculoVax™ priming followed by VesiculoVax™ boosting has completed several dose-escalation clinical trials for HIV-1 and Ebola. These clinical trials demonstrated safety, 100% vaccine take, and immunogenicity across a range of doses. Isfahan virus, a second immunologically distinct vesiculovirus vector developed by Auro Vaccines in collaboration with the University of Texas Medical Branch at Galeveston has demonstrated protective efficacy in a small animal model of lethal encephalitic disease caused by Venezuelan and Eastern equine encephalitis viruses. VesiculoVax™ viral vector vaccines have demonstrated rapid-onset, single-doseprotection of non-human primates against hemorrhagic fever viruses such as Ebola, Marburg, and Lassa. ,
- DNA priming followed by VesiculoVax™ boosting has completed Phase 1 clinical evaluation as an HIV-1 vaccine. The data demonstrate the safety and tolerability of this technology and confirm that VesiculoVax™ boosting following DNA priming synergistically enhances T cell immune responses beyond those seen with DNA vaccines alone.